Initial Public Offering
Baird served as a co-manager in this transaction
AboutTESARO, Inc. (“TESARO” or the “Company”) (NasdaqGM: TSRO) recently completed an initial public offering of 6,000,000 shares of its common stock at a price of $13.50 per share, generating gross proceeds of approximately $81 million. The Company intends to use the net proceeds from the offering to fund clinical trials, acquire or in-license product candidates and for working capital and general corporate purposes.
TESARO is an oncology-focused biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics and supportive care products to improve the lives of cancer patients. The Company has in-licensed and is currently developing three product candidates; rolapitant, niraparib and TSR-011. TESARO intends to continue to leverage the experience and competencies of the Company’s management team to identify, acquire, develop and commercialize additional pharmaceutical products and product candidates that are safer and more effective than current therapies in the treatment and support of cancer patients. TESARO is based in Waltham, Massachusetts.
For additional information about this transaction, please contact:
- July 2012
- TESARO, Inc.
- Target Location
- North America